Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Based on 2 Wall Street analysts offering 12 month price targets for Grifols SA in the last 3 months. The average price target is $16.88 with a high forecast of $16.88 and a low forecast of $16.88. The average price target represents a 134.12% change from the last price of $7.21.
Brookfield Asset Management is in talks with Grifols' majority shareholders to potentially privatize the company. The market is navigating between optimism over Brookfield's offer and setbacks from credit rating agencies and banks.
As of August 2024 Grifols has a market cap of $6.02 Billion. This makes Grifols the world's 2374th most valuable company by market cap according to our data.
The Grifols, S.A. stock prediction for 2025 is currently $ 7.37, assuming that Grifols, S.A. shares will continue growing at the average yearly rate as they did in the last 10 years.
Historical dividend payout and yield for Grifols, S.A (GRFS) since 2015. The current TTM dividend payout for Grifols, S.A (GRFS) as of August 02, 2024 is $0.00. The current dividend yield for Grifols, S.A as of August 02, 2024 is 0.00%.
The short seller accused Grifols of manipulating its debt-to-earnings figures by consolidating earnings of units it doesn't control, meaning leverage was likely double reported levels, and said shares were “uninvestible.” The Spanish company rejected Gotham City's research as “false information and speculations.”
High Leverage Pressures Rating: Grifols' ratings are under pressure due to high leverage (Fitch-defined). EBITDA leverage in particular rose sharply towards 10x (9x net) in 2021 and peaked at 10.7x (10.3x net) in 2022 as a result of pandemic-driven temporary operating underperformance and a EUR1.
Grifols shares fell Thursday after Moody's Ratings downgraded the Spanish pharmaceutical company's credit rating, citing in part its high indebtedness, opaque organizational structure and financial performance.
Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of GRFS, demonstrate its potential to perform inline with the market. It currently has a Growth Score of D.
Total debt on the balance sheet as of June 2024 : $11.40 B
According to Grifols's latest financial reports the company's total debt is $11.40 B. A company's total debt is the sum of all current and non-current debts.
BioLife Plasma Services is among the top payers in the plasma donation industry. New donors at BioLife can earn up to $900 in their first month through various promotions and bonuses.
Grifols is a leading manufacturer of plasma-derived therapies, essentially used in treating patients suffering from rare genetic diseases or severe infections. Grifols captured the third position with a market share of 12.8% in 2021.
Introduction: My name is Kimberely Baumbach CPA, I am a gorgeous, bright, charming, encouraging, zealous, lively, good person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.
